The V617F mutation of JAK2 (JAK2 V617F ) is specific of myeloproliferative disorders (MPDs) and its detection is now one of the first tests performed in the diagnostic work-up of polycythemia and thrombocytoses. [1] [2] [3] The JAK2 V617F allele burden varies depending on the type of MPD, with the majority of polycythemia vera (PV) expressing 450% JAK2 V617F and essential thrombocythemia (ET) expressing o50% mutant 4, 5 in Table 1 The JAK2 V617F allelic ratio in whole blood and in granulocytes in relation to the % neutrophils. ET  20  73  13  18  92  12  13  415  ET  21  69  14  20  89  14  16  447  ET  16  74  13  18  ND  15  ND  414  ET  17  73  18  25  91  16  18  167  ET  21  67  13  19  84  17  20  472  ET  8  85  14  16  92  17  18  425  ET  11  76  18  24  79  20  25  428  ET  8  82  21  26  89  26  29  214  ET  21  71  37  52  87  54  62  450  PV  24  65  1  2  91  1  1  229  PV  15  80  15  19  77  15  19  439  PV  14  77  21  27  93  24  26  445  PV  21  66  16  24  90  26  29  416  PV  10  79  75  95  89  89  100  419  PV  4  94  93  99  94  92  98  443  PV  7  86  88  102  98  96  98  451  IMF  14  76  23  30  96  24  25 Mean+s. 420  ET  33  56  6  11  86  7  8  436  ET  14  74  9  12  96  13  14  473  ET  30  60  6  10  84  15  18  412  ET  20  65  16  25  82  16  20  391  ET  34  62  62  100  60   a   68  113  393  PV  23  65  2  3  86  2  2  448  PV  28  59  6  10  92  10  11  410  PV  29  61  12  20  81  16  20  465  PV  17  70  28  40  94  36  38  441  PV  21  67  26  39  85  51  60  390  IMF  24  48   b   2  4  5 9   c   5  8  392  IMF  18  63  15  24  65  25 purified granulocytes, the source of DNA typically used to study the JAK2 V617F allelic ratio. However, granulocyte purification being time-consuming, many diagnostic laboratories opt to work on whole blood instead. There are potential problems with using DNA extracted from whole blood rather than purified granulocytes. B and T lymphocytes typically do not express JAK2 V617F , which implies that the JAK2 V617F burden is likely to be underestimated in whole blood assays. Moreover, some PV and half of JAK2-mutated ET express o15% JAK2 V617F : such low levels of mutant, often missed by sequencing, are detected in purified granulocytes by sensitive allele-specific PCR (AS-PCR) techniques. In whole blood assays however, some of the patients with low levels of mutant might be found negative.
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We used a allele-specific, quantitative PCR (AS-qPCR) that detects 0.1% JAK2 V617F in granulocytes 5, 6 to compare results obtained with genomic DNA extracted from whole blood or purified blood granulocytes. Forty-eight consecutive patients, 41 with MPDs (12 PV, 26 ET and three idiopathic myelofibrosis (IMF)) and seven with secondary erythrocytosis (SE), were examined. Twelve MPD patients (five PV, five ET and two IMF) had been receiving cytoreductive treatment (pipobroman or hydroxyurea); all other patients were examined at the time of diagnosis. Aliquots of whole blood and pellets of purified granulocytes were prepared from the same sample, as described 5, 7 and stored at À201C (whole blood) or À801C (granulocyte pellets) until use. Whole blood DNA and granulocyte DNA were prepared using QiaAmp DNA mini-kits (Qiagen) following the manufacturers' instructions. JAK2 ASqPCRs were performed at least in duplicate with 25 ng DNA per reaction, as described previously; 5, 6 copy numbers were determined by comparison with serial dilutions of plasmids containing wild-type and V617F JAK2 DNA amplicons.
The JAK2 status (JAK2 V617F -positive or -negative) of patients was identical in whole blood and in purified granulocytes: 36 MPD patients were found positive for JAK2 V617F including the two patients with 1% mutant (Table 1) ; all SE and five ET were JAK2 V617F -negative. A good correlation was found between the % JAK2 V617F found in whole blood and the % JAK2 V617F measured in purified granulocytes (n ¼ 36, r ¼ 0.98, Po0.001). The JAK2 V617F allelic ratio was 15% lower on average in whole blood than in granulocytes; underestimation of the % JAK2 V617F was similar in PV (À18%) and ET (À11%, P ¼ 0.320). MPD patients had on average 19% lymphocytes (JAK2 V617F -negative cells), o10% monocytes and 70% neutrophils in whole blood whereas granulocyte preparations contained on average 86% neutrophils and o5% lymphocytes and monocytes, the rest being eosinophils (Table 1) . Thus, the degree of underestimation of the JAK2 V617F allelic ratio measured in whole blood likely depends on the % neutrophils. Indeed, when the % JAK2 V617F observed were corrected for the % neutrophils in the DNA preparation, % JAK2 V617F in whole blood were no longer underestimated: compared to purified granulocytes, the median variation of the % JAK2 V617F in whole blood was 0% (corrected) vs À14% (observed).
We then analysed the effect of cytoreductive drugs on the assessment of the JAK2 V617F allele burden. For the 24 untreated patients (seven PV, 16 ET and one IMF), the % JAK2 V617F in whole blood correlated with the % JAK2 V617F in purified granulocytes (n ¼ 24, r ¼ 0.99, Po0.001) (Figure 1a) . The % JAK2 V617F in whole blood also correlated with the white blood cell (WBC) counts (n ¼ 24, r ¼ 0.83, Po0.001), as reported previously 5 and with the % neutrophils in blood (n ¼ 24, r ¼ 0.51, P ¼ 0.01). The 12 patients with cytoreductive treatment (five PV, five ET, two IMF) were characterized by lower WBC counts (6.472.7 Â 10 9 /l vs 11.776.4, P ¼ 0.010), a lower % neutrophils (62 vs 74% Po0.001) and a higher % lymphocytes (24 vs 17%, P ¼ 0.006) ( Table 1) . For treated patients, the % JAK2 V617F in whole blood and the % of neutrophils were no longer correlated. This was not due to the small size of the series, as correlations persisted for groups of 12 patients selected randomly among patients at diagnosis. However, the % JAK2 V617F in whole blood and the % JAK2 V617F in granulocytes were correlated (n ¼ 12, r ¼ 0.95, Po0.001) (Figure 1b) . The average underestimation of JAK2 V617F burden in whole blood was -8% for patients at diagnosis but -29% for treated patients (P ¼ 0.002). When the % JAK2 V617F observed was corrected by the % neutrophils in the DNA preparation, % JAK2 V617F in whole blood and % JAK2 V617F in granulocytes remained well correlated (n ¼ 24, r ¼ 0.99, Po0.001 for patients at diagnosis; n ¼ 12, r ¼ 0.97, Po0.001 for treated patients). However, in contrast to patients at diagnosis, the variation of the % JAK2 V617F measured in whole blood of treated patients was not significantly reduced when adjusted for the % neutrophils in blood (Table 1) . Reasons for the lack of correction are unclear. Treated patients had high % of both lymphocytes and monocytes (75% had 410% monocytes in blood, vs 25% of patients at diagnosis); unlike lymphocytes, monocytes carry JAK2 V617F but they have been shown to express the mutation less frequently than granulocytes. 8 Several of the treated patients also had an abnormally high % of eosinophils, the level of JAK2 V617F expression of which is unknown (Table 1) . Last, although there is so far no clear evidence of it, the possibility that mutated granulocytes may be more sensitive to the cytoreductive effect of hydroxyurea and pipobroman than non-mutated granulocytes cannot be excluded.
In summary, provided that the AS-qPCR used is sensitive (i.e., detects o1% JAK2 V617F ), there is no false negative when JAK2 V617F is detected in whole blood. Hence, whole blood is Correlations between the % JAK2 V617F observed in whole blood and the % JAK2 V617F observed in purified granulocytes. Letters to the Editor suitable for the diagnosis of MPD including those with as little as 1% mutant; the JAK2 V617F burden thus measured is lower than in purified granulocytes and may be adjusted using the % neutrophils. For the follow-up of the mutated clone in treated patients, however, it is advisable to assess JAK2 V617F before and during treatment in the same population of purified cells as blood cell ratios are altered and the variation of the JAK2 V617F burden measured in whole blood increases and no longer correlates with blood parameters. For the purpose of assessing the JAK2 V617F burden during treatment, blood granulocytes remain the easiest cells to obtain and purify. CD95 (Fas/Apo-1) and TNF-related-apoptosis-inducing-ligand (TRAIL/Apo-2) are two of the six cellular receptors belonging to the TNF superfamily regulating the extrinsic apoptotic pathways after the interaction with their cognate ligand. Both CD95 and TRAIL are potential candidates to target apoptosis in malignant cells, even if their simple expression is not an essential feature for apoptosis sensitivity. 1 In preclinical studies, the administration of soluble recombinant TRAIL (rTRAIL) or anti-CD95 agonistic antibody in experimental animals induced significant tumor regression without systemic toxicity. 2, 3 This approach can be used to overcome chemotherapy resistance, for example, several types of leukemias; in this case, tumor resistance can be bypassed by a combined therapy including the activation of death receptors (DR; extrinsic pathway) and chemotherapy (intrinsic way). 1 In this contest, a plethora of naturally occurring molecules with potential chemopreventive properties have been recently described. 4 Among these, quercetin (3,3 0 ,4 0 ,5,7-pentahydroxyflavone), the major dietary flavonoid, abundantly present in a broad range of fruits and vegetables, has been intensively studied for its antioxidant, antiinflammatory, antiproliferative and, more recently, apoptotic effects in cell cultures and animal models. 5 We have previously shown that quercetin, at 50 mM concentration, sensitized HPB-ALL cells to CD95-mediated apoptosis. 6, 7 The same cell line was strongly resistant to TRAIL treatment (up to 50 ng/ml), both in terms of caspase 3 activation and cell viability (Table 1 ). This observation confirmed the unusual resistance of HPB-ALL cells, similarly to acute lymphoblastic leukemias, to DR-mediated apoptotic stimuli. Quercetin was able to bypass this resistance only in the presence of a functional CD95 receptor; 6 in fact, the enhancement effect of anti-CD95 and quercetin was confirmed by poly(ADP-ribose) polymerase (PARP) degradation. The immunoblot reported in Figure 1a shows the degradation of PARP (120 kDa) by caspase 3 with the appearance of the 85-kDa inactive fragment. On the opposite, quercetin was incapable of sensitizing HPB-ALL cells to rTRAIL induction, although TRAIL-R2 was clearly detectable by immunoblotting (data not shown), suggesting the possible expression of an inactive form of the receptor.
Jurkat cell line was reported to be very responsive to both TRAIL and anti-CD95 inducers, and similarly to HPB-ALL, Jurkat cells are sensitive to the enhancement activity of anti-CD95 and quercetin. When quercetin was associated with anti-CD95 or rTRAIL, caspase 3 activity increased 3-and 2.5-fold, respectively, compared to the treatment with DRs alone (Table 1 ). The enhancing effect of TRAIL and quercetin on Jurkat cells was also confirmed by cell viability (Table 1) and PARP degradation (Figure 1b ). These results demonstrate that quercetin enhanced DR-dependent apoptosis in Jurkat cells, a lymphoid cell line partially sensitive to CD95 and TRAIL induction.
To confirm the large spectrum of activity of quercetin in enhancing DR-mediated apoptosis observed in the two lymphoid cell lines described above, we measured its effect on K-562 and U-937, two myeloid cell lines, chosen for their different sensitivities to death ligands and for their ability to differentiate in vitro. Table 1 shows that K-562 cells were
